MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$9,389K
Free Cash flow
-$42,830K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds, net of 1,725 and 2,757...
Stock-based compensation
Accrued expenses and other curre...
Others
Negative Cash Flow Breakdown
Net loss
Accounts receivable
Inventory, current and non-curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Loss on note
-
-
0
-1,159
Inventory write-off
0
-
-649
1,318
Amortization of debt discount
0
-
0
65
Loss on extinguishment of debt
0
0
0
-2,092
Bad debt expense
-
-
0
31
Issuance costs from derivative instruments
0
-
0
1,837
Net loss
-40,552
-40,194
-46,910
-77,111
Depreciation and amortization
619
555
488
1,437
Stock-based compensation
2,256
1,970
1,789
4,228
Accounts receivable
2,986
2,548
2,789
-170
Inventory, current and non-current
2,903
-2,369
-364
-1,362
Prepaid expenses and other current assets
1,485
278
1,002
2,159
Other non-current assets
-1,573
3,742
-
-
Accounts payable
-596
1,533
-738
3,732
Lease liabilities and right-of-use (rou) asset, net
80
80
-285
-18
Accrued expenses and other current liabilities
1,751
-2,063
10,082
1,663
Net cash used in operating activities
-42,243
-42,318
-39,650
-60,194
Issuance of note
0
-
0
2,012
Proceeds from note
-
-
853
-
Purchase of property and equipment
587
1,692
1,874
1,495
Net cash used in investing activities
-587
-1,692
-1,021
-3,507
Payment of term loan
0
-
0
9,650
Repurchase of common stock
0
-
7,811
5,949
Proceeds from espp
0
79
-
-
Proceeds from the exercise of options
16
-
-
-
Proceeds, net of 1,725 and 2,757 expenses, from sale of common stock
33,489
20,126
66,954
170,986
Net cash provided by financing activities
33,505
20,205
59,143
155,387
Effect of currency rate change on cash
-64
6
-14
-17
Net (decrease) increase in cash, cash equivalents and restricted cash
-9,389
-23,799
18,458
91,669
Cash, cash equivalents and restricted cash beginning of the period
186,008
209,807
191,349
99,680
Cash, cash equivalents and restricted cash end of period
176,619
186,008
209,807
191,349
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds, net of 1,725 and
2,757 expenses, from...
$33,489K
Proceeds from the
exercise of options
$16K
Net cash provided by
financing activities
$33,505K
Net (decrease)
increase in cash, cash...
-$9,389K
Canceled cashflow
$33,505K
Stock-based compensation
$2,256K
Accrued expenses and
other current...
$1,751K
Other non-current
assets
-$1,573K
Depreciation and
amortization
$619K
Lease liabilities and
right-of-use (rou) asset, net
$80K
Net cash used in
operating activities
-$42,243K
Canceled cashflow
$6,279K
Net cash used in
investing activities
-$587K
Effect of currency rate
change on cash
-$64K
Net loss
-$40,552K
Accounts receivable
$2,986K
Inventory, current and
non-current
$2,903K
Prepaid expenses and
other current assets
$1,485K
Accounts payable
-$596K
Purchase of property and
equipment
$587K
Buy us a coffee
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)